CBI digs deep into Emaar MGF, grills MD Shravan Gupta
The CBI on Wednesday questioned EMAAR MGF's managing director Shravan Gupta on the ongoing probe into the alleged disproportionate assets case of Kadapa MP Jaganmohan Reddy, son of late chief minister YS Rajasekhar Reddy.
https://www.moneycontrol.com/news/business/cnbc-tv18-comments/-1412763.html

The ED has again started clamping down on those involved in the AgustaWestland VVIP helicopter scam. In this episode, the ED on Wednesday raided businessman Shravan Gupta and seven places related to him. Gupta, a former director of the real-state company Emaar MGF, tightened his grip on Shravan Gupta and searched seven locations in Delhi and Gurugram in connection with the Rs 3600-crore AgustaWestland VVIP helicopter. The ED suspects that Gupta's wire Associated with money laundering,…

Former Emaar MGF Land Limited Managing Director Shravan Gupta has laundered the money generated from the Rs 3,600 crore AgustaWestland VVIP chopper deal case into bank accounts of his four shell companies located in several tax havens, sources in the Enforcement Directorate said.

​Gupta, against whom a non-bailable warrant was issued by Delhi’s Rouse Avenue Court in August, informed the court that he would not be able to travel to India to join the probe as he has “diabetes, high…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India's first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation's first mRNA-based Covid-19 vaccine. It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the human body to make a…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India’s first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation’s first mRNA-based Covid-19 vaccine. It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the human body to make a…

Delhi court has refused to cancel the non-bailable warrants (NBWs) against Shravan Gupta, the former managing director of realty major Emmar MGF, in connection with the AgustaWestland VVIP chopper money laundering case, saying he was not cooperating in the investigation. The court said Gupta's application seeking cancellation of the NBWs was without any merit and also noted that the warrant was issued against him on August 29 as he did not join the investigation despite receipt of summons…

A Delhi court has refused to cancel the non-bailable warrants (NBWs) against Shravan Gupta, the former managing director of realty major Emmar MGF, in connection with the AgustaWestland VVIP chopper money laundering case, saying he was not cooperating in the investigation.

The court said Gupta's application seeking cancellation of the NBWs was without any merit and also noted that the warrant was issued against him on 29 August as he did not join the investigation despite receipt of…

First indigenous mRNA Covid-19 vaccine received DCGI approval on Tuesday, for Phase II/III clinical trials to examine its protective efficacy. The Indian mRNA vaccine against Covid-19 is created by Gennova Biopharmaceuticals Ltd, a Pune-based biotechnology company in partnership with the Department of Biotechnology. “It is a matter of pride that Nation’s first mRNA-based vaccine is found to be safe and the Drugs Controller General of India has approved the phase II/III trial. This is an…

Since the central government has set a production target of 60 million doses for the country’s first mRNA Covid-19 vaccine by the end of the year, Dr Sanjay Singh, CEO of Gennova Pharmaceuticals, said production is being ramped up.

“It has been a tough journey but this is a new platform and we have to innovate to find solutions. We are trying to put our best foot forward and ramp up production,” Singh told The Indian Express on Thursday.…

India-based Gennova Biopharmaceuticals Ltd. confirmed it had been granted authorization to conduct phase 2/3 clinical trials for the mRNA-based COVID-19 vaccine candidate HGCO19.

Gennova submitted the proposed Phase II and Phase III study entitled “A Prospective, Multicentre, Randomized, Active-controlled, Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate safety and tolerability, and immunogenicity of the vaccine candidate HGCO19 in healthy…

The Enforcement Directorate (ED) on Wednesday carried out multiple searches on premises of Shravan Gupta, the former managing director of realty major Emmar MGF, and some others in connection with the AgustaWestland VVIP chopper money laundering case, officials said.

Raids are being carried out at nine premises in Delhi, Gurgaon and a few other locations in the National Capital Region, they said.

The searches are aimed at collecting evidence in connection with the Rs…

In a major development in the AgustaWestland VVIP Chopper scam, the Special Court in New Delhi on Tuesday refused to cancel the non-bailable warrants (NBWs) issued against former managing director of realty major Emaar MGF Shravan Gupta.

The Delhi Court added that it was 'clear' from the conduct of Shravan that he was not cooperative in the case considering that he had not complied with nine summons that had been issued to him by the Encofremnet Directorate (ED). The Court thereby…

Indian pharmaceutical firm Gennova Biopharmaceuticals’ COVID-19 vaccine, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said

Government authorities have also approved further studies to test the vaccine’s efficacy in a larger population. Gennova plans to conduct a mid-stage study at about 10 to 15 sites and a late-stage trial at 22 to 27 sites in India…

India has approved further clinical trials for its first homegrown mRNA-based COVID-19 vaccine developed by Gennova Biopharmaceuticals Ltd, the government said on Tuesday, after the shot was found to be safe and effective in an early-stage study.

Gennova is among a few pharmaceutical firms worldwide, including Moderna Inc (MRNA.O) and Pfizer Inc (PFE.N), to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the…

India’s vaccine development efforts have got a further fillip with the first mRNA-based Covid-19 vaccine candidate HGCO19, being developed by Pune-based Emcure Pharmaceuticals' subsidiary Gennova Biopharmaceuticals, entering into the next stage of clinical trials.

A few days ago, India had approved the world's first plasmid DNA vaccine, ZycoV-D from Zydus Cadila. The Drug Controller General of India yesterday approved Phase II and Phase III study protocols for HGCO19, following the…

Indian firm Gennova Biopharmaceuticals working on the nation's first mRNA-based COVID-19 vaccine, submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India's National Regulatory Authority (NRA).

Vaccine Subject Expert Committee (SEC) reviewed the interim Phase I data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study.

Gennova submitted the proposed Phase…

India's first indigenous mRNA Covid-19 vaccine candidate, which is being developed by Pune-based Gennova Biopharmaceuticals Limited, has been found safe, tolerable, and immunogenic in the participants of the phase-1 study.

Gennova Biopharmaceuticals had submitted the interim clinical data of the Phase I study of the vaccine to the Central Drugs Standard Control Organisation (CDSCO), which is the Indian drug regulatory authority.

Read more at…

India has approved further clinical trials for its first homegrown mRNA-based COVID-19 vaccine, developed by Gennova Biopharmaceuticals, after the shot is found to be safe and effective in an early-stage study.

The country has authorised emergency use for two domestically developed COVID-19 jabs, made by Bharat Biotech and Zydus Cadila, but does not have mRNA-based vaccines yet in its immunisation programme before a potential third coronavirus wave.…

Gennova Biopharmaceuticals’ mRNA-based COVID-19 vaccine has submitted the interim clinical data of the phase-I study to the Central Drugs Standard Control Organisation (CDSCO).

The Vaccine Subject Expert Committee (SEC) reviewed the interim phase-I data and found that HGCO19 was safe, tolerable and immunogenic in the participants of the study.

Gennova submitted the proposed phase-II and phase-III study entitled, “A prospective, multi-centre, randomised, active-controlled,…

India’s first domestically developed mRNA-based Covid-19 vaccine candidate has been found safe in its interim Phase 1 clinical trials, and the national drugs regulator has granted approval to its maker, Pune-based Gennova Biopharmaceuticals, to begin Phase 2/3 trials, the Union ministry of science and technology said on Tuesday.

The development of HGCO19, the country’s first vaccine based on messenger-RNA (mRNA) technology, is a key step in India’s target of vaccinating all adults by…